Supernus Pharmaceuticals reports strong demand rebound after resolving supply constraints in March 2026

Supernus Pharmaceuticals announced a strong rebound in patient initiations and prescriptions in March 2026 following the resolution of previous supply constraints. Despite earlier supply issues, demand remained robust, with physicians continuing to submit patient forms and maintain waitlists. The company received around 500 new patient forms in Q4 2025 and an additional 400 in Q1 2026, showing sustained interest. Supernus is now focused on processing these forms quickly to deliver new shipments and get patients on therapy.